BioMarin Pharmaceutical
Tracked across 4 events · 24 articles · First seen Apr 17, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BioMarin is the lead developer of the ASO medicine, leveraging its genetic medicine expertise. The collaboration could strengthen its pipeline and market position in rare diseases.
Jul 27, 2026 · 6 articles
Business
Impact: BioMarin is the acquirer, completing the purchase of Alesta to add ALE1 to its skeletal conditions portfolio. The deal strengthens its rare disease pipeline and aligns with its strategy, though it will be modestly dilutive to 2026 earnings.
Aug 19, 2026 · 6 articles
Business
Impact: BioMarin grants a license and receives royalties, ending costly litigation and providing a new revenue stream, though it loses some exclusivity rights.
Aug 31, 2026 · 6 articles
Tech
Impact: BioMarin Pharmaceutical is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track BioMarin Pharmaceutical live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard